Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Clouser, Christine L ^a   Holtz, Colleen M ^a   Mullett, Mary ^e   Crankshaw, Duane L ^e   Briggs, Jacquie E ^e   Chauhan, Jay ^b   Vanhoutan, Ilze Matise ^d   Patterson, Steven E ^a,b   Mansky, Louis M ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN M; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; RIBONUCLEOTIDE REDUCTASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; SPLEEN SIZE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; PATHOLOGY; SPLEEN;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MURINE LEUKEMIA VIRUS; MUS;

ANIMALS; ANTI-RETROVIRAL AGENTS; CELLS, CULTURED; DEOXYCYTIDINE; DISEASE PROGRESSION; IMMUNOGLOBULIN M; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; RIBONUCLEOTIDE REDUCTASES; SPLEEN; VIRAL LOAD;

EID: 79251562519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015840     Document Type: Article

References (34)

1. Clouser CL, Patterson SE, Mansky LM (2010) Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol 84: 9301-9309.
2. Lombardi VC, Ruscetti FW, Gupta JD, Pfost MA, Hagen KS, et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326: 585-589.
3. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. (2006) Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2: e25.
4. Bebenek K, Roberts JD, Kunkel TA (1992) The effects of dNTP pool imbalances on frameshift fidelity during DNA replication. J Biol Chem 267: 3589-3596.
5. Lori F, Lisziewicz J (1999) Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther 4: 101-108.
6. Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, et al. (2010) Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. Arch Virology 45: 66-71.
7. Mayhew CN ML, Chendil D, Ahmed MM, Phillips JD, Greenberg RN, Elford HL, Gallicchio VS (2002) Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res 56: 167-181.
8. Mayhew CN, Mampuru LJ, Chendil D, Ahmed MM, Phillips JD, et al. (2002) Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res 56: 167-181.
9. Mayhew C, Oakley O, Piper J, Hughes NK, Phillips J, et al. (1997) Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). Cell Mol Biol (Noisy-le-grand) 43: 1019-1029.
10. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, et al. (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 29,29-difluorodeoxycytidine. Mol Pharmacol 38: 567-572.
11. Wong A, Soo RA, Yong W-P, Innocenti F (2009) Clinical pharmacology and pharmacokinetics of gemcitabine. Drug Metabolism Reviews 41: 77-88.
12. Dias ASP, Bester MJ, Britz RF, Apostolides Z (2006) Animal models used for the evaluation of antiretroviral therapies. Current HIV Research 4: 431-446.
13. Ohnota H, Okada Y, Ushijima H, Kitamura T, Komuro K, et al. (1990) 39- Azido-39-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening. Antimicrobial Agents and Chemotherapy 34: 605-609.
14. Rossi L, Serafini S, Franchetti P, Casabianca A, Orlandi C, et al. (2002) Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)- 2-(phosphonomethoxypropyl)adenine. Journal of Antimicrobial Chemotherapy 50: 639-647.
15. Mosier DE, Yetter RA, Morse HC, 3rd (1987) Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med 165: 1737-1742.
16. Pattengale PK, Taylor CR, Twomey P, Hill S, Jonasson J, et al. (1982) Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV). Am J Pathol 107: 362-377.
17. Simard C, Huang M, Jolicoeur P (1995) Establishment of leukemic T-cell lines from mice inoculated with the MAIDS defective virus. Virology 206: 555-563.
18. Yetter RA, Buller RM, Lee JS, Elkins KL, Mosier DE, et al. (1988) CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J Exp Med 168: 623-635.
19. Casabianca A, Orlandi C, Fraternale A, Magnani M (2004) Development of a real-time PCR assay using SYBR Green for provirus load quantification in a murine model of AIDS. J Clin Microbiol 42: 4361-4364.
20. Chattopadhyay SK, Morse HC, 3rd, Makino M, Ruscetti SK, Hartley JW (1989) Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci U S A 86: 3862-3866.
21. Chattopadhyay SK, Sengupta DN, Fredrickson TN, Morse HC, 3rd, Hartley JW (1991) Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice. J Virol 65: 4232-4241.
22. Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, et al. (2006) Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. J Gastroenterol 41: 70-76.
23. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. The FASEB Journal 22: 659-661.
24. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, et al. (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52: 6958-6961.
25. Morse HCI, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, et al. (1992) Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6: 607-621.
26. Chattopadhyay SK, Morse HCI, Makino M, Ruscetti SK, Hartley JW (1989) Defective virus is associated with induction of murine retrovirus-induced immunodeficiency syndrome. Proc Natl Acad Sci U S A 86: 3862-3866.
27. Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse HCI (1989) Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differeing susceptibility of inbred mouse strains. J Virol 63: 1223-1231.
28. Casabianca A, Orlandi C, Fraternale A, Magnani M (2004) Development of a real-time PCR assay using SYBR Green I for provirus load quantification in a murine model of AIDS. J Clin Microbiol 42: 4361-4364.
29. Harrington RD, Geballe AP (1993) Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol 67.
30. Vodicka MA, Goh WC, Wu LI, Rogel ME, Bartz SR, et al. (1997) Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233: 193-198.
31. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
32. Bartz SR, Vodicka MA (1997) Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12: 337-342.
33. Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse III HC (1989) Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J Virol 63: 1223-1231.
34. Morse HCr, Hartley JW, Tang Y, Chattopadhyay SK, Giese N, et al. (1994) Lymphoproliferation as a precursor to neoplasia: what is a lymphoma In: Minson A, Neil J, McCrae M, eds. Viruses and Cancer. Cambridge: Cambridge University Press. pp 265-291.